Literature DB >> 21604267

Tau splicing and the intricacies of dementia.

Athena Andreadis1.   

Abstract

Tau is a microtubule-associated protein that fulfills several functions critical for neuronal formation and health. Tau discharges its functions by producing multiple isoforms via regulated alternative splicing. These isoforms modulate tau function in normal brain by altering the domains of the protein, thereby influencing its localization, conformation, and post-translational modifications and hence its availability and affinity for microtubules and other ligands. Disturbances in tau expression result in disruption of the neuronal cytoskeleton and formation of tau structures (neurofibrillary tangles) found in brains of dementia sufferers. More specifically, aberrations in tau splicing regulation directly cause several neurodegenerative diseases, which lead to dementia. In this review, I present our cumulative knowledge of tau splicing regulation in connection with neurodegeneration and also briefly go over the still-extensive list of questions that are connected to tau (dys)function.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21604267      PMCID: PMC3177961          DOI: 10.1002/jcp.22842

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  49 in total

Review 1.  Functional implications of the association of tau with the plasma membrane.

Authors:  Amy M Pooler; Diane P Hanger
Journal:  Biochem Soc Trans       Date:  2010-08       Impact factor: 5.407

Review 2.  Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases.

Authors:  Athena Andreadis
Journal:  Biochim Biophys Acta       Date:  2005-01-03

Review 3.  Frontotemporal dementia with tau pathology.

Authors:  Laura Gasparini; Beatrice Terni; Maria Grazia Spillantini
Journal:  Neurodegener Dis       Date:  2007       Impact factor: 2.977

4.  The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

Authors:  Nichole E LaPointe; Gerardo Morfini; Gustavo Pigino; Irina N Gaisina; Alan P Kozikowski; Lester I Binder; Scott T Brady
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

5.  RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5' splice site.

Authors:  Amar Kar; Kazuo Fushimi; Xiaohong Zhou; Payal Ray; Chen Shi; Xiaoping Chen; Zhiren Liu; She Chen; Jane Y Wu
Journal:  Mol Cell Biol       Date:  2011-02-22       Impact factor: 4.272

Review 6.  Probing the biology of Alzheimer's disease in mice.

Authors:  Karen H Ashe; Kathleen R Zahs
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

Review 7.  Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease.

Authors:  Lars M Ittner; Jürgen Götz
Journal:  Nat Rev Neurosci       Date:  2010-12-31       Impact factor: 34.870

Review 8.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

Review 9.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

10.  Heterogeneous nuclear ribonucleoprotein E3 modestly activates splicing of tau exon 10 via its proximal downstream intron, a hotspot for frontotemporal dementia mutations.

Authors:  Yan Wang; Lei Gao; Sze-Wah Tse; Athena Andreadis
Journal:  Gene       Date:  2009-11-12       Impact factor: 3.688

View more
  30 in total

1.  Tau isoform composition influences rate and extent of filament formation.

Authors:  Qi Zhong; Erin E Congdon; Haikady N Nagaraja; Jeff Kuret
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

2.  Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture.

Authors:  Hans Zempel; Frank J A Dennissen; Yatender Kumar; Julia Luedtke; Jacek Biernat; Eva-Maria Mandelkow; Eckhard Mandelkow
Journal:  J Biol Chem       Date:  2017-05-23       Impact factor: 5.157

3.  Saitohin, which is nested within the tau gene, interacts with tau and Abl and its human-specific allele influences Abl phosphorylation.

Authors:  Yan Wang; Lei Gao; Christopher G Conrad; Athena Andreadis
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

Review 4.  Structure and mechanism of action of tau aggregation inhibitors.

Authors:  Katryna Cisek; Grace L Cooper; Carol J Huseby; Jeff Kuret
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

Review 5.  Modeling the complex pathology of Alzheimer's disease in Drosophila.

Authors:  Pedro Fernandez-Funez; Lorena de Mena; Diego E Rincon-Limas
Journal:  Exp Neurol       Date:  2015-05-27       Impact factor: 5.330

6.  Hsp70 alters tau function and aggregation in an isoform specific manner.

Authors:  Kellen Voss; Benjamin Combs; Kristina R Patterson; Lester I Binder; T Chris Gamblin
Journal:  Biochemistry       Date:  2012-01-23       Impact factor: 3.162

Review 7.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

8.  Association of rs62063857 variant of the saitohin gene with Parkinson's disease.

Authors:  Ezgi Sonmez; Mavi Deniz Ozel; Eylul Ece Islek; Ali Sazci; Halil Atilla Idrisoglu
Journal:  Cell Mol Neurobiol       Date:  2014-08-29       Impact factor: 5.046

9.  An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease.

Authors:  Taner Shakir; Ahmed Y Coulibaly; Patrick G Kehoe
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

Review 10.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.